Tag
A nationwide English cohort study (n≈13.9M) found transient but significant increases in rare vascular and inflammatory events after first SARS‑CoV‑2 infection and a smaller, short-lived increase in myocarditis/pericarditis after first BNT1
A large target‑trial emulation of US claims data found continued oral anticoagulation after ≥90 days for unprovoked VTE markedly reduced recurrent VTE and mortality, increased major bleeding, but produced an overall net clinical benefit tha
Continued oral anticoagulant therapy after ≥90 days for unprovoked VTE significantly lowers recurrence and mortality despite increased bleeding risk, offering a net clinical benefit consistent across anticoagulant types and treatment durati
A nurse-driven, patient-centered education bundle significantly reduced missed doses of venous thromboembolism prophylaxis in a community hospital, demonstrating scalable improvements in prophylaxis adherence beyond academic centers.
Extended low-dose apixaban significantly reduces recurrent venous thromboembolism (VTE) in patients with provoked VTE and enduring risk factors, with minimal major bleeding. Reduced-dose apixaban for cancer-associated VTE is equally effecti
A randomized trial demonstrates that low-dose apixaban for 12 months significantly lowers symptomatic recurrent VTE risk after provoked events with enduring risk factors, with minimal major bleeding.
The pilot PARTUM trial demonstrates the feasibility of a large-scale multi-national randomized study assessing low-dose aspirin versus placebo for postpartum venous thromboembolism prevention in moderate-risk individuals, supporting further
A national French study reveals that cold agglutinin syndrome (CAS) develops about 10 days after Mycoplasma pneumoniae infection onset, often requiring ICU care and transfusions, with a generally favorable prognosis despite frequent venous
An 8.3% incidence of VTE was observed in newly diagnosed lymphoma patients in Vietnam, with pretreatment elevated D-dimer and cardiovascular comorbidities as key risk factors, emphasizing the need for tailored thromboprophylaxis.
Low-dose aspirin added to anticoagulation for cancer-associated VTE reduces recurrence and PE-related mortality but increases bleeding risk, without improving overall survival or net clinical benefit over 6 months.
